Literature DB >> 29319304

ATP Site Ligands Determine the Assembly State of the Abelson Kinase Regulatory Core via the Activation Loop Conformation.

Rajesh Sonti1, Ines Hertel-Hering1, Allan Joaquim Lamontanara2, Oliver Hantschel2, Stephan Grzesiek1.   

Abstract

The constituent SH3, SH2, and kinase domains of the Abl kinase regulatory core can adopt an assembled (inactive) or a disassembled (active) conformation. We show that this assembly state strictly correlates with the conformation of the kinase activation loop induced by a total of 14 ATP site ligands, comprising all FDA-approved Bcr-Abl inhibiting drugs. The disassembly of the core by certain (type II) ligands can be explained by an induced push on the kinase N-lobe via A- and P-loop toward the SH3 domain. A similar sized P-loop motion is expected during nucleotide binding and release, which would be impeded in the assembled state, in agreement with its strongly reduced kinase activity.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29319304     DOI: 10.1021/jacs.7b12430

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  6 in total

1.  How ATP-Competitive Inhibitors Allosterically Modulate Tyrosine Kinases That Contain a Src-like Regulatory Architecture.

Authors:  Linglan Fang; Jessica Vilas-Boas; Sujata Chakraborty; Zachary E Potter; Ames C Register; Markus A Seeliger; Dustin J Maly
Journal:  ACS Chem Biol       Date:  2020-06-23       Impact factor: 5.100

2.  Imatinib can act as an Allosteric Activator of Abl Kinase.

Authors:  Tao Xie; Tamjeed Saleh; Paolo Rossi; Darcie Miller; Charalampos G Kalodimos
Journal:  J Mol Biol       Date:  2021-11-10       Impact factor: 5.469

3.  Structural Insights into Characterizing Binding Sites in Epidermal Growth Factor Receptor Kinase Mutants.

Authors:  Zheng Zhao; Lei Xie; Philip E Bourne
Journal:  J Chem Inf Model       Date:  2019-01-11       Impact factor: 4.956

4.  Mechanistic Insights Into Co-Administration of Allosteric and Orthosteric Drugs to Overcome Drug-Resistance in T315I BCR-ABL1.

Authors:  Hao Zhang; Mingsheng Zhu; Mingzi Li; Duan Ni; Yuanhao Wang; Liping Deng; Kui Du; Shaoyong Lu; Hui Shi; Chen Cai
Journal:  Front Pharmacol       Date:  2022-03-18       Impact factor: 5.810

5.  Bcr-Abl Allosteric Inhibitors: Where We Are and Where We Are Going to.

Authors:  Francesca Carofiglio; Daniela Trisciuzzi; Nicola Gambacorta; Francesco Leonetti; Angela Stefanachi; Orazio Nicolotti
Journal:  Molecules       Date:  2020-09-14       Impact factor: 4.411

6.  Differential impact of BTK active site inhibitors on the conformational state of full-length BTK.

Authors:  Raji E Joseph; Thomas E Wales; Neha Amatya; D Bruce Fulton; John R Engen; Amy Andreotti
Journal:  Elife       Date:  2020-11-23       Impact factor: 8.140

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.